Related references
Note: Only part of the references are listed.Safety and clinical activity of the Notch inhibitor, crenigacestat (LY3039478), in an open-label phase I trial expansion cohort of advanced or metastatic adenoid cystic carcinoma
C. Even et al.
INVESTIGATIONAL NEW DRUGS (2020)
Accumulated cytotoxicity of CDK inhibitor dinaciclib with first-line chemotherapy drugs in salivary adenoid cystic carcinoma cells
Laijun Xu et al.
ODONTOLOGY (2020)
Patients with adenoid cystic carcinomas of the salivary glands treated with lenvatinib: Activity and quality of life
Laura D. Locati et al.
CANCER (2020)
A Phase II Trial of Pembrolizumab and Vorinostat in Recurrent Metastatic Head and Neck Squamous Cell Carcinomas and Salivary Gland Cancer
Cristina P. Rodriguez et al.
CLINICAL CANCER RESEARCH (2020)
Risk factors for survival and distant metastasis in 125 patients with head and neck adenoid cystic carcinoma undergoing primary surgery
In Seong Jeong et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2020)
Oligometastatic head and neck cancer: Comprehensive review
Toms Vengaloor Thomas et al.
HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK (2020)
Stereotactic body radiotherapy for medically unfit patients with cancers to the head and neck
Hossam Al-Assaf et al.
HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK (2020)
ATR is a MYB regulated gene and potential therapeutic target in adenoid cystic carcinoma
Mattias K. Andersson et al.
ONCOGENESIS (2020)
A phase II study on the efficacy and toxicity of cabozantinib in recurrent/metastatic salivary gland cancer patients.
Wim van Boxtel et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Randomized phase II study of axitinib versus observation in patients with recurred or metastatic adenoid cystic carcinoma.
Bhumsuk Keam et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Reirradiation of salivary gland tumors with carbon ion radiotherapy at CNAO
B. Vischioni et al.
RADIOTHERAPY AND ONCOLOGY (2020)
Prognostic Impact of PD-L1 Expression in Malignant Salivary Gland Tumors as Assessed by Established Scoring Criteria: Tumor Proportion Score (TPS), Combined Positivity Score (CPS), and Immune Cell (IC) Infiltrate
Hanno M. Witte et al.
CANCERS (2020)
Clinicopathologic implications of Myb and Beta-catenin expression in adenoid cystic carcinoma
Susan Park et al.
JOURNAL OF OTOLARYNGOLOGY-HEAD & NECK SURGERY (2020)
ACCURACY a phase II trial of AL101, a selective gamma secretase inhibitor, in subjects with recurrent/metastatic (R/M) adenoid cystic carcinoma (ACC) harboring Notch activating mutations (Notchmut)
R. Ferrarotto et al.
ANNALS OF ONCOLOGY (2020)
Long-term outcomes and clinicogenomic correlates in recurrent, metastatic adenoid cystic carcinoma
Glenn J. Hanna et al.
ORAL ONCOLOGY (2020)
Prognostic nomogram in patients with metastatic adenoid cystic carcinoma of the salivary glands
Stefano Cavalieri et al.
EUROPEAN JOURNAL OF CANCER (2020)
PARP Inhibition Increases the Reliance on ATR/CHK1 Checkpoint Signaling Leading to Synthetic Lethality-An Alternative Treatment Strategy for Epithelial Ovarian Cancer Cells Independent from HR Effectiveness
Patrycja Gralewska et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)
Salivary Gland Cancer in the Era of Routine Next-Generation Sequencing
Emilija Todorovic et al.
HEAD & NECK PATHOLOGY (2020)
Clinically Integrated Molecular Diagnostics in Adenoid Cystic Carcinoma
Julia Thierauf et al.
ONCOLOGIST (2019)
Phase II Study of Lenvatinib in Patients With Progressive, Recurrent or Metastatic Adenoid Cystic Carcinoma
Vatche Tchekmedyian et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
NISCAHN: A phase II, multicenter nonrandomized trial aiming at evaluating nivolumab (N) in two cohorts of patients (pts) with recurrent/metastatic (R/M) salivary gland carcinoma of the head and neck (SGCHN), on behalf of the Unicancer Head & Neck Group.
Jerome Fayette et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
A phase II trial cohort of nivolumab plus ipilimumab in patients (Pts) with recurrent/metastatic adenoid cystic carcinoma (R/M ACC).
Vatche Tchekmedyian et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial
David A. Palma et al.
LANCET (2019)
Phase II trial with axitinib in recurrent and/or metastatic salivary gland cancers of the upper aerodigestive tract
Laura D. Locati et al.
HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK (2019)
Clinical outcome of stereotactic body radiotherapy for lung-only oligometastatic head and neck squamous cell carcinoma: Is the deferral of systemic therapy a potential goal?
Pierluigi Bonomo et al.
ORAL ONCOLOGY (2019)
Prognostic importance of the lymphovascular invasion in head and neck adenoid cystic carcinoma: A systematic review and meta-analysis
Barbara Martins-Andrade et al.
ORAL ONCOLOGY (2019)
Genetic hallmarks of recurrent/metastatic adenoid cystic carcinoma
Allen S. Ho et al.
JOURNAL OF CLINICAL INVESTIGATION (2019)
IGF2/IGF1R Signaling as a Therapeutic Target in MYB-Positive Adenoid Cystic Carcinomas and Other Fusion Gene-Driven Tumors
Mattias K. Andersson et al.
CELLS (2019)
Immune microenvironment and evasion mechanisms in adenoid cystic carcinomas of salivary glands
Carla Mosconi et al.
ORAL ONCOLOGY (2019)
Pembrolizumab for the Treatment of Advanced Salivary Gland Carcinoma Findings of the Phase 1b KEYNOTE-028 Study
Roger B. Cohen et al.
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS (2018)
A phase I dose-escalation and dose-expansion study of brontictuzumab in subjects with selected solid tumors
R. Ferrarotto et al.
ANNALS OF ONCOLOGY (2018)
Mortality risk after clinical management of recurrent and metastatic adenoid cystic carcinoma
Melody J. Xu et al.
JOURNAL OF OTOLARYNGOLOGY-HEAD & NECK SURGERY (2018)
Low SOX2 expression marks a distinct subset of adenoid cystic carcinoma of the head and neck and is associated with an advanced tumor stage
Julia Thierauf et al.
PLOS ONE (2018)
Ataxia-Telangiectasia-Mutated Protein Expression as a Prognostic Marker in Adenoid Cystic Carcinoma of the Salivary Glands
Shadavlonjid Bazarsad et al.
YONSEI MEDICAL JOURNAL (2018)
Mutation analysis of the EGFR pathway genes, EGFR, RAS, PIK3CA, BRAF, and AKT1, in salivary gland adenoid cystic carcinoma
Kosuke Saida et al.
Oncotarget (2018)
Genetic rearrangements, hotspot mutations, and microRNA expression in the progression of metastatic adenoid cystic carcinoma of the salivary gland
Simon Andreasen et al.
Oncotarget (2018)
Differences in patterns of survival in metastatic adenoid cystic carcinoma of the head and neck
Stijn van Weert et al.
HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK (2017)
Management of salivary gland carcinomas - a review
Xiaoli Wang et al.
ONCOTARGET (2017)
Activating NOTCH1 Mutations Define a Distinct Subgroup of Patients With Adenoid Cystic Carcinoma Who Have Poor Prognosis, Propensity to Bone and Liver Metastasis, and Potential Responsiveness to Notch1 Inhibitors
Renata Ferrarotto et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Clinical prognostic factors of salivary adenoid cystic carcinoma: A single-center analysis of 61 patients
Robert Cordesmeyer et al.
JOURNAL OF CRANIO-MAXILLOFACIAL SURGERY (2017)
Lung metastasectomy in adenoid cystic cancer: Is it worth it?
Lara Girelli et al.
ORAL ONCOLOGY (2017)
Unlocking the chromatin of adenoid cystic carcinomas using HDAC inhibitors sensitize cancer stem cells to cisplatin and induces tumor senescence
Luciana O. Almeida et al.
STEM CELL RESEARCH (2017)
Prognostic significance of p53 immunohistochemical expression in adenoid cystic carcinoma of the salivary glands: a meta-analysis
Qinglin Li et al.
ONCOTARGET (2017)
A phase 2 study of vorinostat in locally advanced, recurrent, or metastatic adenoid cystic carcinoma
Priscila H. Goncalves et al.
ONCOTARGET (2017)
Transcriptomes define distinct subgroups of salivary gland adenoid cystic carcinoma with different driver mutations and outcomes
Candace A. Frerich et al.
Oncotarget (2017)
Comprehensive genomic profiles of metastatic and relapsed salivary gland carcinomas are associated with tumor type and reveal new routes to targeted therapies
J. S. Ross et al.
ANNALS OF ONCOLOGY (2017)
Tumor Volume Doubling Time of Pulmonary Metastases Predicts Overall Survival and Can Guide the Initiation of Multikinase Inhibitor Therapy in Patients With Metastatic, Follicular Cell-Derived Thyroid Carcinoma
Mona M. Sabra et al.
CANCER (2017)
Phase II trial of dasatinib for recurrent or metastatic c-KIT expressing adenoid cystic carcinoma and for nonadenoid cystic malignant salivary tumors
S. J. Wong et al.
ANNALS OF ONCOLOGY (2016)
Adenoid cystic carcinoma: A review of recent advances, molecular targets, and clinical trials
Patrick M. Dillon et al.
HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK (2016)
A phase II study of axitinib (AG-013736) in patients with incurable adenoid cystic carcinoma
A. L. Ho et al.
ANNALS OF ONCOLOGY (2016)
A phase II study of sorafenib in recurrent and/or metastatic salivary gland carcinomas: Translational analyses and clinical impact
L. D. Locati et al.
EUROPEAN JOURNAL OF CANCER (2016)
The role of perineural invasion on head and neck adenoid cystic carcinoma prognosis: a systematic review and meta-analysis
Jun Ju et al.
ORAL SURGERY ORAL MEDICINE ORAL PATHOLOGY ORAL RADIOLOGY (2016)
Phase 2 study of dovitinib in patients with metastatic or unresectable adenoid cystic carcinoma
Bhumsuk Keam et al.
CANCER (2015)
Adenoid cystic carcinoma of the head and neck - An update
Andres Coca-Pelaz et al.
ORAL ONCOLOGY (2015)
Pattern of recurrent disease in major salivary gland adenocystic carcinoma
Karoliina Hirvonen et al.
VIRCHOWS ARCHIV (2015)
Adenoid cystic carcinoma: current therapy and potential therapeutic advances based on genomic profiling
Young Kwang Chae et al.
ONCOTARGET (2015)
Phase II trial of sorafenib in advanced salivary adenoid cystic carcinoma of the head and neck
David J. Thomson et al.
HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK (2015)
Efficacy of nelfinavir as monotherapy in refractory adenoid cystic carcinoma: Results of a phase II clinical trial
Andrew C. Hoover et al.
HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK (2015)
Diagnostic and therapeutic implications of new molecular biomarkers in salivary gland cancers
Goran Stenman et al.
ORAL ONCOLOGY (2014)
Clinicopathological study of distant metastases of salivary adenoid cystic carcinoma
M. Gao et al.
INTERNATIONAL JOURNAL OF ORAL AND MAXILLOFACIAL SURGERY (2013)
Mutation signature of adenoid cystic carcinoma: evidence for transcriptional and epigenetic reprogramming
Henry F. Frierson et al.
JOURNAL OF CLINICAL INVESTIGATION (2013)
Clinical Characteristics and Prognostic Factors of Adenoid Cystic Carcinoma of the Head and Neck
Yunsuk Choi et al.
LARYNGOSCOPE (2013)
Adenoid cystic carcinoma of the head and neck: A single-center analysis of 105 consecutive cases over a 30-year period
Stijn van Weert et al.
ORAL ONCOLOGY (2013)
Adenoid cystic carcinoma of the head and neck
Christopher J. Balamucki et al.
AMERICAN JOURNAL OF OTOLARYNGOLOGY (2012)
Adenoid cystic carcinoma of the head and neck
Christopher L. Ellington et al.
CANCER (2012)
Phase II study of cisplatin and imatinib in advanced salivary adenoid cystic carcinoma
Niladri Ghosal et al.
BRITISH JOURNAL OF ORAL & MAXILLOFACIAL SURGERY (2011)
A Phase 2 Trial of Bortezomib Followed by the Addition of Doxorubicin at Progression in Patients With Recurrent or Metastatic Adenoid Cystic Carcinoma of the Head and Neck A Trial of the Eastern Cooperative Oncology Group (E1303)
Athanassios Argiris et al.
CANCER (2011)
Systemic therapy in the management of metastatic or locally recurrent adenoid cystic carcinoma of the salivary glands: a systematic review
Scott A. Laurie et al.
LANCET ONCOLOGY (2011)
Prognostic factors in malignant tumours of the salivary glands
Paul M. Speight et al.
BRITISH JOURNAL OF ORAL & MAXILLOFACIAL SURGERY (2009)
Survival from salivary glands adenoid cystic carcinoma in European populations
Laura Ciccolallo et al.
ORAL ONCOLOGY (2009)
Cetuximab in recurrent and/or metastatic salivary gland carcinomas: A phase II study
L. D. Locati et al.
ORAL ONCOLOGY (2009)
Notch Signalling and the Regulation of Angiogenesis
Arndt F. Siekmann et al.
CELL ADHESION & MIGRATION (2007)
A phase II study of imatinib for advanced adenoid cystic carcinoma of head and neck salivary glands
M. Raphael Pfeffer et al.
ORAL ONCOLOGY (2007)
Adenoid cystic carcinoma of the head and neck treated by surgery with or without postoperative radiation therapy: Prognostic features of recurrence
Allen M. Chen et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2006)
Salivary gland carcinoma: Independent prognostic factors for locoregional control, distant metastases, and overall survival: Results of the Dutch Head and Neck Oncology Cooperative Group
CHJ Terhaard et al.
HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK (2004)
Adenoid cystic carcinoma of the head and neck - a 20 years experience
H Kokemueller et al.
INTERNATIONAL JOURNAL OF ORAL AND MAXILLOFACIAL SURGERY (2004)
Clinicopathologic predictors and impact of distant metastasis from adenoid cystic carcinoma of the head and neck
MW Sung et al.
ARCHIVES OF OTOLARYNGOLOGY-HEAD & NECK SURGERY (2003)
Share Paper
